We are building an industry-leading pipeline based on our deep understanding of T-cell biology and its interaction with cancer.
Our vision is a world where treatment with a single, safe, and effective cell therapy delivers lasting remissions or even cures for patients with cancer.
We are a fully integrated company capable of discovering innovative technologies, translating science into new therapies, manufacturing cell therapy products, and executing robust clinical trials, all in our quest to defeat cancer.
We own and operate the LyFE Manufacturing Center™ in Bothell, Washington. With our own manufacturing facility, we are able to mitigate risk, control our supply chain, maximize efficiencies, and rapidly incorporate advancements and new innovations into our cell therapy product candidates.
We believe that our expert team, with deep cell therapy manufacturing experience, as well as our capabilities, are significant advantages. At full staffing and capacity, LyFE can manufacture more than 1,200 patient CAR T‑cell products a year, supporting our clinical trials and potential commercial launches of approved products.
We are focused on rapidly advancing two clinical programs for patients with aggressive forms of cancer.
Our lead program, rondecabtagene autoleucel, or ronde-cel, is under evaluation in two pivotal clinical trials for patients with aggressive large B-cell lymphoma.
Our second product candidate, LYL273, is in Phase 1 clinical development for patients with refractory metastatic colorectal cancer.
We are building the team and infrastructure that is needed to seamlessly execute multiple late-stage clinical development programs and successful commercial launches.